EU-SolidAct

EU-SolidAct is part of the EU-RESPONSE project who has received funding from the European Union’s Horizon 2020 Research and Innovation Program under grant agreement No 101015736. @EUScienceInnov

🆕#IPDMA on #JAKinhibitors in #COVID19 patients in🏥. Many trials were conducted, but several❓❔❓ unanswered -> jakinhibitoripdma.org In collaboration with @OCBE_UniOslo, @ClinEpiBasel, @Inserm, a patient representative, @EU_SolidAct and 10 other participating trial teams

Results of the Bari-SolidAct clinical trial, conducted in 14 European countries, have been published in Critical Care. eu-response.eu/eu-solidact-pu… pubmed.ncbi.nlm.nih.gov/36627655/

DMC/DSMB members do very valuable and mostly unappreciated work in RCTs. Thank you very much drs. @stefano_vella, Du, Medaglini, Jacobs, vd Werf, Medaglini, @pocock_stuart, @phaikyeong, Barnes, Yeni and Collier for excellent work in our DMC!

We’re pleased to announce that our lead candidate, #bemcentinib, has been selected for inclusion in a pan-European research project exploring potential treatments for hospitalised COVID-19 patients, the @EU_SolidAct trial. Read the release here: bergenbio.com/investors/stoc… #AXL

@BGenBio and @Oslounivsykehus announce the AXL Inhibitor Bemcentinib will be Studied in the EU Funded @EU_SolidAct trial in Hospitalised COVID-19 Patients eu-response.eu/bergenbio-and-… @EUScienceInnov/@Inserm/@ECRIN_ERIC

Now Austria and and the Medical University of Innsbruck has included their first patient in the EU-SolidAct trial on Baricitinib treatment @EUScienceInnov/@ECRIN_ERIC/@Oslounivsykehus/@Inserm

Happy to inform that we have now reached 200 randomised patients! We have opened 45 sites in 10 countries, with more to follow. @EUScienceInnov / @ECRIN_ERIC / @Oslounivsykehus / @Inserm

Happy to inform that Belgium and Luxembourg have now included their first patients, making them the 6th and 7th country with more to come!

New paper from the DisCoVeRy and the @EU_SolidAct EU-RESPONSE group with @DKFBasel contribution by Matthias Briel: "Europe, despite its diversity, must be capable of responding unanimously and rapidly to any health crisis": bit.ly/3HPM3yE #platformtrial #COVID19

Happy to inform that we have now reached 100 randomised patients! We are recruiting in 33 sites in 5 countries, with more to follow. @EUScienceInnov/@ECRIN_ERIC/@Oslounivsykehus/ @Inserm

Baricitinib/placebo has arrived @LovisenbergSH! @simenws and colleagues are ready to include their first patient in the Trial as the eight European site.

Happy to inform that the two first patients are included, the first at the world's northernmost university hospital @UNN_HF with PI A Kildal and the second in @SykehusVestfold with PI @dr_asgeir! @EUScienceInnov / @ECRIN_ERIC / @Oslounivsykehus / @Inserm

Den nye Europeiske plattformstudien for COVID-19 og fremtidige pandemier, EU-SolidAct, har nå startet å inkludere pasienter ved norske sykehus. Studien skal gå i 15 land og ledes av OUS. bit.ly/EU_SolidAct / @EU_SolidAct / @ECRIN_ERIC / @Inserm/ @EUScienceInnov

@EU_SolidAct Baricitinib is in the house! Aleksander has everything ready and set to include the first patient!

EU SolidAct, a new platform trial for emerging pandemics, today starts testing new drugs for severe COVID-19, aiming to improve treatment options and to strengthen European pandemic preparedness bit.ly/EU_SolidAct / @EU_SolidAct / @ECRIN_ERIC / @Inserm / @EUScienceInnov